Funding - December 10, 2014
Sweden to Invest More in Climate Change, Life Sciences
In the draft Swedish federal budget for 2015, the government proposes that the mandate of the Fourier transform be changed. Today the fund, which manages 3 billion, focuses on the automotive industry. But according to the proposal, the mission instead becomes to directly or indirectly invest in small to medium sized businesses in the early stages […]
Uncategorized - December 10, 2014
Study: Therapy Helps OCD
A study by researchers from Denmark, Norway and Sweden demonstrated that cognitive behavioral therapy (CBT) can reduce the amount of symptoms in children diagnosed with obsessive compulsive disorder (OCD). The study involved 260 children and adolescents with OCD and almost half the children were entirely free of their OCD symptoms after the first phase of […]
Agreement - December 10, 2014
MSD, Denmark to Partner
Life sciences company MSD (known as Merck in the U.S. and Canada) has entered into a strategic partnership with the University of Copenhagen and the Capital Region. The Capital Region is one of five regional governing bodies in Denmark assigned to region-wide issues such as health care. This strategic partnership comes soon after a similar agreement with Novartis […]
Collaboration - December 9, 2014
Swedish, Welsh Hubs to Partner
Medicon Village, a Swedish cluster for life sciences, visited Wales’ new center for life sciences this month. The visit builds on a relationship which began 18 months ago when Life Sciences Hub Wales was chosen as Medicon Village’s first “twin.” The two organizations identified a number of areas where they can share knowledge and collaborate. […]
Regulatory compliance - December 9, 2014
AstraZeneca Scores Victory in Pay-for-Delay Case
In what could become a significant decision for the pharmaceutical industry, a jury in U.S. federal court found that AstraZeneca’s deal with Ranbaxy Laboratories to settle a patent fight over its heartburn medication Nexium did not violate antitrust laws. A group of pharmacies, wholesalers and insurers had sued over the agreement. As Bloomberg reported, this is the […]
Clinical Trials - December 9, 2014
Promising Hemophilia Drug
Novo Nordisk announced a new analysis of phase 3 data demonstrating people with hemophilia A who had the highest annualized bleeding rate (ABR) during initial treatment with NovoEight® (turoctocog alfa) showed the largest reduction in bleeding over the duration of treatment. Data for the recombinant factor VIII (rFVIII) product NovoEight®were presented at the 56th Annual Meeting of the […]
